129 related articles for article (PubMed ID: 8648382)
21. High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study.
Nastoupil LJ; McLaughlin P; Feng L; Neelapu SS; Samaniego F; Hagemeister FB; Ayala A; Romaguera JE; Goy AH; Neal E; Wang M; Fayad L; Fanale MA; Oki Y; Westin JR; Rodriguez MA; Cabanillas F; Fowler NH
Br J Haematol; 2017 Apr; 177(2):263-270. PubMed ID: 28340281
[TBL] [Abstract][Full Text] [Related]
22. Primary treatment of low-grade non-Hodgkin's lymphoma with the combination of fludarabine and mitoxantrone: a phase II study of the Hellenic Cooperative Oncology Group.
Dimopoulos MA; Fountzilas G; Papageorgiou E; Kiamouris C; Mantzios G; Anagnostopoulos A; Nicolaides C; Economopoulos T;
Leuk Lymphoma; 2002 Jan; 43(1):111-4. PubMed ID: 11908713
[TBL] [Abstract][Full Text] [Related]
23. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
Rummel M; Kaiser U; Balser C; Stauch M; Brugger W; Welslau M; Niederle N; Losem C; Boeck HP; Weidmann E; von Gruenhagen U; Mueller L; Sandherr M; Hahn L; Vereshchagina J; Kauff F; Blau W; Hinke A; Barth J;
Lancet Oncol; 2016 Jan; 17(1):57-66. PubMed ID: 26655425
[TBL] [Abstract][Full Text] [Related]
24. [Evaluation of the clinical effectivity and toxicity of the FDN regimen (fludarabin, mitoxantron, dexamethason) in patients with follicular lymphoma].
Oborilová A; Mayer J; Korístek Z; Hofmanová Z; Vásová I; Navrátil M; Vinklárková J; Muzikárová M; Klabusay M; Matuska M
Cas Lek Cesk; 2004; 143(10):685-90. PubMed ID: 15584619
[TBL] [Abstract][Full Text] [Related]
25. Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501.
Velasquez WS; Lew D; Grogan TM; Spiridonidis CH; Balcerzak SP; Dakhil SR; Miller TP; Lanier KS; Chapman RA; Fisher RI;
J Clin Oncol; 2003 May; 21(10):1996-2003. PubMed ID: 12743154
[TBL] [Abstract][Full Text] [Related]
26. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
27. A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma.
Zinzani PL; Tani M; Fanti S; Stefoni V; Musuraca G; Vitolo U; Perrotti A; Fina M; Derenzini E; Baccarani M
Cancer; 2008 Feb; 112(4):856-62. PubMed ID: 18189293
[TBL] [Abstract][Full Text] [Related]
28. A new model for predicting infectious complications during fludarabine-based combination chemotherapy among patients with indolent lymphoid malignancies.
Tam CS; Wolf MM; Januszewicz EH; Grigg AP; Prince HM; Westerman D; Seymour JF
Cancer; 2004 Nov; 101(9):2042-9. PubMed ID: 15372472
[TBL] [Abstract][Full Text] [Related]
29. [Treatment of lymphoma patients with fludarabine-based regimens: a report of 29 cases].
Huang HQ; Jiang WQ; Peng YL; Xia ZJ; Li YH; Li XB; Lin TY; Sun XF; Guan ZZ
Ai Zheng; 2004 Apr; 23(4):448-51. PubMed ID: 15087037
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma.
Karmali R; Kassar M; Venugopal P; Shammo JM; Fung HC; Bayer R; O'Brien T; Gregory SA
Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):467-74. PubMed ID: 21700527
[TBL] [Abstract][Full Text] [Related]
31. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia.
Bosch F; Ferrer A; López-Guillermo A; Giné E; Bellosillo B; Villamor N; Colomer D; Cobo F; Perales M; Esteve J; Altés A; Besalduch J; Ribera JM; Montserrat E;
Br J Haematol; 2002 Dec; 119(4):976-84. PubMed ID: 12472576
[TBL] [Abstract][Full Text] [Related]
32. Phase II study of low-grade non-Hodgkin lymphomas with fludarabine and mitoxantrone followed by rituximab consolidation: promising results in marginal zone lymphoma.
Economopoulos T; Psyrri A; Fountzilas G; Tsatalas C; Anagnostopoulos A; Papageorgiou S; Xiros N; Dimopoulos MA
Leuk Lymphoma; 2008 Jan; 49(1):68-74. PubMed ID: 18203014
[TBL] [Abstract][Full Text] [Related]
33. Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone.
Sarris AH; Jiang Y; Tsimberidou AM; Thomaides A; Rassidakis GZ; Ford RJ; Medeiros LJ; Cabanillas F; McLaughlin P
Semin Oncol; 2002 Feb; 29(1 Suppl 2):48-55. PubMed ID: 11842389
[TBL] [Abstract][Full Text] [Related]
34. Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma.
Luminari S; Marcheselli L; Sacchi S; Pozzi S; Bari A; Ilariucci F; Stelitano C; Angrilli F; Lazzaro A; Baldini L
Cancer; 2009 May; 115(9):1906-13. PubMed ID: 19248044
[TBL] [Abstract][Full Text] [Related]
35. The immunosuppression and potential for EBV reactivation of fludarabine combined with cyclophosphamide and dexamethasone in patients with lymphoproliferative disorders.
Lazzarino M; Orlandi E; Baldanti F; Furione M; Pagnucco G; Astori C; Arcaini L; Viglio A; Paulli M; Gerna G; Bernasconi C
Br J Haematol; 1999 Dec; 107(4):877-82. PubMed ID: 10606897
[TBL] [Abstract][Full Text] [Related]
36. [Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
Forstpointner R; Hänel A; Repp R; Hermann S; Metzner B; Pott C; Hartmann F; Rothmann F; Böck HP; Wandt H; Unterhalt M; Hiddemann W
Dtsch Med Wochenschr; 2002 Oct; 127(43):2253-8. PubMed ID: 12397539
[TBL] [Abstract][Full Text] [Related]
37. New initiatives with fludarabine monophosphate in hematologic malignancies.
Keating MJ; O'Brien S; Robertson LE; Kantarjian H; Dimopoulos M; McLaughlin P; Cabanillas F; Gregoire V; Yang LY; Gandhi V
Semin Oncol; 1993 Oct; 20(5 Suppl 7):13-20. PubMed ID: 7694371
[TBL] [Abstract][Full Text] [Related]
38. Fludarabine, mitoxantrone and dexamethasone as front-line therapy in elderly patients affected by newly-diagnosed, low-grade non-Hodgkin's lymphomas with unfavorable prognostic factors: results of a phase II study.
Bordonaro R; Petralia G; Restuccia N; Todaro AM; Serraino D; Giuffrida D; Cordio S; Giannitto-Giorgio C; Salice P; Ursino M; Novello G; Marletta F; Manusia M
Leuk Lymphoma; 2004 Jan; 45(1):93-100. PubMed ID: 15061203
[TBL] [Abstract][Full Text] [Related]
39. Low-grade non-Hodgkin's lymphoma--development of a new effective combination regimen (fludarabine, mitoxantrone and dexamethasone; FND).
Keating MJ; McLaughlin P; Cabanillas F
Eur J Cancer Care (Engl); 1997 Dec; 6(4 Suppl):21-6. PubMed ID: 9460339
[TBL] [Abstract][Full Text] [Related]
40. Use of fludarabine-containing chemotherapeutic regimen results in durable complete remission of subcutaneous panniculitis-like T-cell lymphoma.
Chim CS; Loong F; Ng WK; Kwong YL
Am J Clin Dermatol; 2008; 9(6):396-8. PubMed ID: 18973407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
